Novo Slashes Lilly Obesity Drug Prices for US Cash Buyers
Novo Nordisk A/S has announced a significant price reduction for its obesity drugs, targeting cash-pay patients in the U.S. This move is aimed at enhancing its market presence against competitor Eli Lilly & Co.
Novo’s Competitive Pricing Strategy
Starting Monday, Novo will offer introductory doses of its popular medications, Wegovy and Ozempic, at a rate of $199 per month. This discount applies for the first two months of treatment, offering patients an affordable option to start their weight management journey.
Following this initial period, patients can continue accessing these drugs through NovoCare, the company’s direct-to-consumer portal, at a cost of $349 per month. This price is 30% lower than the current self-pay rate.
Price Comparison with Eli Lilly
- Novo’s pricing for Wegovy and Ozempic is now competitive with Eli Lilly’s Zepbound.
- The new price matches Lilly’s cost for a lower dose of Zepbound.
- Novo’s pricing is lower than that of higher doses of Zepbound.
This pricing strategy reflects Novo’s commitment to capturing a larger share of the U.S. obesity treatment market. The price reduction is indicative of the growing competition in the pharmaceutical sector, particularly in the field of obesity management.
By making these drugs more accessible, Novo aims to attract more patients while challenging Eli Lilly’s dominance in the market. The company’s focus on affordability could significantly impact the choices available to individuals seeking effective obesity treatments in the United States.
